Skip to main content
. 2013 May;15(5):544–553. doi: 10.1593/neo.13168

Figure 5.

Figure 5

Efficient inhibition of s.c. tumor growth by CAR-modified T cells in vivo. (A–C) The suppression of tumorigenicity of A549 cells by CAR-modified T cells. CAR-transfected lymphocytes and A549 tumor cells were co-inoculated s.c. at a ratio of 10:1. Tumorigenicity of the animals was monitored and calculated every 3 days (A). All of the mice were sacrificed and the mean tumor volume was calculated. Bars, means ± SD (*P < .05) (B and C). (D–G) Inhibition of the tumor growth by CAR-modified T lymphocytes. A431 or A2780 tumor cells were implanted s.c. into NOD/SCID mice at day 0. Once tumors had grown to 200 to 500 mm3, animals were grouped and i.v. injected with CAR-modified T cells on days 23, 24, and 25. (D) Tumor volume of A431 tumors. Bars, means ± SD. (E) Survival of animals bearing A431 tumors. (F) Tumor volume of A2780 tumors. Bars, means ± SD. (G) Survival of animals bearing A2780 tumors.